Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ana Gimenez-Capitan"'
Autor:
G. Crespo, Elisabeth Pérez-Ruiz, Maria Gonzalez-Cao, Ana Gimenez Capitan, Maria de los Llanos Gil, Rafael Rosell, Daniela Morales-Espinosa, Delvys Rodriguez-Abreu, Niki Karachaliou, Santiago Viteri Ramirez, Salvador Martin Algarra, Teresa Puertolas, Miguel Angel Molina-Vila, Erika Aldeguer, Ivan Marquez Rodas, R. Blanco, Cristina Teixidó, Ana Drozdowskyj, Maria Angeles Royo
Publikováno v:
Journal of Clinical Oncology. 35:11504-11504
11504 Background: PD-L1 can be induced by oncogenic signals or up-regulated via INFG in a STAT1- and NFκB-dependent manner. STAT3 opposes STAT1-mediated anti-tumor immune responses. I kappa B kinase epsilon (IKBKE) is an interferon signaling inducer
CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients
Autor:
Ana Gimenez Capitan, Rafael Rosell, Jordi Bertran-Alamillo, Silvia Garcia-Roman, Miguel Angel Molina-Vila, Niki Karachaliou, Santiago Viteri Ramirez, Pedro Mendez, Daniela Morales-Espinosa
Publikováno v:
Journal of Clinical Oncology. 34:11581-11581
11581Background: Targeted therapy has improved outcomes in EGFR mutated and ALK translocated NSCLC but options for squamous cell carcinoma and KRAS-mutated tumors remain scarce. Genome re-replicati...
Autor:
Baorui Liu, Ana Gimenez Capitan, Rafael Rosell, Jia Wei, Nandie Wu, Jose Javier Sanchez, Lixia Yu
Publikováno v:
Journal of Clinical Oncology. 33:e15075-e15075
e15075 Background: 5-fluorouracil,oxaliplatin, and docetaxel chemotherapy are commonly used in the treatment for gastric cancer (GC). Apoptosis relevant genes might be associated with drug resistan...
Autor:
Enric Carcereny Costa, Ana Gimenez Capitan, Radj Gervais, Rafael Rosell, Daniela Morales-Espinosa, Niki Karachaliou, Enriqueta Felip, Bartomeu Massuti, Teresa Moran, Andres Felipe Cardona Zorrilla, Patrick C. Ma, Elisabetta Crisetti, Imane Chaib, Margarita Majem, Santiago Viteri Ramirez, Rosario Garcia Campelo, Alberto Verlicchi, Jose Luis Ramirez, Ana Drozdowskyj
Publikováno v:
Journal of Clinical Oncology. 32:8072-8072
8072 Background: Sixty percent of EGFR-mutant NSCLC p respond to erlotinib, but overall survival (OS) is the same for upfront chemotherapy. Priming BIM, a pro-apoptotic signaling BH3-only protein, induced sensitivity to erlotinib in EGFR-mutant cell
Autor:
Carlos Camps, Bartomeu Massuti, Rut Porta, Miguel Angel Molina-Vila, Joaquim Bosch, Felipe Cardenal, Clara Mayo, Jordi Bertran-Alamillo, Jose Javier Sanchez, Sara Cros, Susana Benlloch, Amaya Gasco, Miquel Taron, Enric Carcereny Costa, Santiago Viteri Ramirez, Ana Gimenez Capitan, Rafael Rosell, Alejandro Martinez-Bueno, Carlota Costa, Laia Capdevila
Publikováno v:
Journal of Clinical Oncology. 30:e18143-e18143
e18143 Background: Advanced NSCLC p with EGFR mutations have a median PFS of 14 months (m) and OS of 27 m when treated with erlotinib. In NSCLC cell lines, tyrosine kinase inhibitors (TKIs) induce p53 translocation from the cytoplasm to the nucleus a